IUPAC: (RS)-2-(methylamino)-1-(4-methylphenyl)propan-1-one · MW 177.24 g/mol · CAS 5650-44-2 (freebase) · C₁₁H₁₅NO
4-methylmethcathinone (4-MMC). β-keto amphetamine · substituted cathinone · the ring-methylated, β-keto cousin of methamphetamine and the cathinone analog of MDMA's release profile. Street/context names: meow meow, M-CAT, drone, bubbles, plant food, MMC.
Mephedrone is a monoamine substrate-releaser, not a pure reuptake blocker. Like amphetamine and MDMA — and unlike cocaine or its own cathinone cousin MDPV — it is transported into the nerve terminal by DAT, NET and SERT, then drives those same carriers into reverse, dumping stored dopamine, noradrenaline and serotonin into the synapse. The defining feature is its lack of selectivity: it releases dopamine and serotonin at overlapping potencies (release EC50 ≈ 49 nM at DAT vs 118 nM at SERT), giving it a hybrid amphetamine-plus-MDMA signature that few other cathinones share.
The protonated amine is recognized as a transported substrate at the DAT central (S1) site, riding the inward Na⁺/Cl⁻ electrochemical gradient into the dopaminergic terminal — the same route used by dopamine itself.
Intracellular mephedrone promotes an inward-facing→outward-facing isomerization that runs the transporter backwards, releasing cytoplasmic dopamine down its gradient (release EC₅₀ ≈ 49 nM, ChEMBL / Simmler 2017).
Crucially, mephedrone is also an efficacious SERT substrate (release EC₅₀ ≈ 118 nM), flooding the synapse with serotonin. This 5-HT component is what separates it from methamphetamine and gives it its MDMA-like empathogenic tint.
Noradrenaline is released with potency between DAT and SERT (release EC₅₀ ≈ 62 nM; Baumann et al. 2012), driving the sympathomimetic core — tachycardia, hypertension, vasoconstriction and thermogenesis.
The β-keto oxygen (the "cathinone" carbonyl) lowers lipophilicity versus methamphetamine, slowing CNS entry slightly and shortening the ketone's half-life — a molecular basis for the abrupt on/off kinetics.
Alongside release, mephedrone weakly blocks reuptake (uptake IC₅₀ ~0.3–3 µM across DAT/NET/SERT; Simmler et al. 2013), so both efflux and inhibited clearance stack to amplify synaptic monoamine build-up.
The pharmacological punchline is the DA:5-HT release ratio of roughly 2.4 : 1 (SERT/DAT EC50 ratio ≈ 2.5, ChEMBL). Pure stimulant cathinones (e.g. cathinone, MDPV) barely touch serotonin; MDMA leans hard the other way, SERT-selective. Mephedrone sits in the middle — enough dopamine release to be compulsively rewarding like an amphetamine, enough serotonin release to feel warm and social like MDMA. That combination is exactly why users binge it, and exactly why the comedown bites.
Mephedrone's most clinically relevant property is its short, steep time-course. Insufflated, effects arrive in minutes and are largely gone within 1–2 hours; orally ("bombed" in paper), onset is 15–45 minutes and duration 2–4 hours. Controlled human pharmacokinetic data are limited — much of what is known comes from user surveys (Winstock et al. 2011) and analytical toxicology rather than formal Phase I studies — but the consistent picture is a brief plasma peak followed by rapid decline. That abrupt fall-off, coupled with dopamine release, is the pharmacological motor behind the drug's hallmark compulsive redosing.
Metabolism cascade: Phase-I metabolism proceeds along three parallel routes — N-demethylation, ketone reduction, and oxidation of the aromatic 4-methyl (tolyl) group — largely CYP2D6-mediated, with conjugation following (Meyer et al. 2010; Pedersen et al. 2013; Khreit et al. 2013). None of the primary metabolites is thought to carry substantial stimulant activity, so the "high" tracks parent drug — which is why it fades fast.
Normephedrone (the N-demethylated primary amine) and 4-carboxy-mephedrone (oxidation of the tolyl methyl through a hydroxytolyl intermediate) are the major urinary markers used in forensic casework, alongside dihydromephedrone from ketone reduction. Because CYP2D6 carries much of the load, CYP2D6 poor metabolizers (~7–10% of Europeans) and anyone co-using CYP2D6 inhibitors (many SSRIs, bupropion) can accumulate higher parent-drug exposure than expected — a real, under-appreciated interaction risk.
Mephedrone's dual dopamine/serotonin release maps onto two overlapping circuit signatures: an amphetamine-like reward-and-arousal drive and an MDMA-like prosocial glow. Because it is non-selective (DA:5-HT release ≈ 2.4 : 1), users describe a genuine hybrid — the stimulant push of speed with some of the empathic warmth of ecstasy — but far shorter, and with a much stronger pull to redose.
Dopamine release in the nucleus accumbens (NAc shell > core) and dorsal striatum mediates the intense euphoria, urge, and locomotor activation. The potent DAT component (release EC₅₀ ≈ 49 nM) places mephedrone's reinforcing efficacy near classical stimulants — it robustly supports self-administration in rodents — which, paired with a 1–2 h offset, produces the drug's defining pattern of dose-stacking every 30–60 minutes across a session.
Simultaneous 5-HT release in limbic and cortical fields (amygdala, ACC, mPFC) supplies the MDMA-like sociability, closeness and mood lift. But serotonin release is a debt taken on credit: repeated redosing depletes releasable 5-HT pools, and the resulting trough underlies the sharp, dysphoric, anxious comedown ("the fear") that mephedrone is notorious for the following day.
NE efflux via NET drives the sympathomimetic burden: tachycardia, hypertension, sweating, bruxism, mydriasis, hyperthermia and peripheral vasoconstriction. This last effect is unusually prominent with mephedrone — the cold, blue or purple fingers, hands and knees reported by users are peripheral vasoconstriction, and they are the visible edge of a whole-body cardiovascular strain that is the drug's main acute danger.
The composite experience: rapid rushing euphoria, talkativeness, disinhibition and craving that peaks and fades within an hour or two, driving the user straight back to the bag. Sessions commonly run all night on escalating redoses. The offset — insomnia, anxiety, low mood, appetite loss, nasal and throat damage from insufflation — is disproportionate to the brief high, and is the part most users underestimate.
The pharmacology also explains the epidemiology. When mephedrone surged around 2009–2010 it was cheap, legal, and widely mislabelled as "plant food" or "bath salts" — a research chemical sold through the gap between molecule and statute. Its short-lived, moreish profile made it a heavy-session drug, and the resulting binge patterns, not any single dose, are what drove most of the harm.
Evidence-based, non-moralistic. Prohibition did not make this molecule safer — it pushed it into an unregulated market where dose, purity and identity are unknown. Accurate information reduces harm; slogans do not.
| Target | Potency | Rel. | Mechanism |
|---|---|---|---|
|
DAT
Dopamine transporter (SLC6A3)
|
EC₅₀ = 49.1 nM
[³H]DA release
|
Substrate-releaser | |
|
NET
Norepinephrine transporter (SLC6A2)
|
EC₅₀ ≈ 62 nM
[³H]NE release
|
Substrate-releaser | |
|
SERT
Serotonin transporter (SLC6A4)
|
EC₅₀ = 118 nM
[³H]5-HT release
|
Substrate-releaser | |
|
SERT : DAT
Release selectivity ratio
|
≈ 2.5
non-selective
|
DA≈NE>5-HT | |
|
DAT (uptake)
Reuptake inhibition
|
IC₅₀ ~0.3–0.8 µM
weak block
|
Weak inhibitor | |
|
SERT (uptake)
Reuptake inhibition
|
IC₅₀ ~2–3 µM
weak block
|
Weak inhibitor |